Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index
Dupilumab is approved for uncontrolled moderate-to-severe atopic dermatitis (AD); cyclosporine is approved for severe AD for <1 year. The efficacy/effectiveness of these treatments was compared indirectly. Regression models used pooled patient-level data to estimate response (Eczema Area and Sev...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2019-06-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3219
|
| _version_ | 1828143577843105792 |
|---|---|
| author | Lieneke F.M. Ariëns Abhijit Gadkari Harmieke van Os-Medendorp Rajeev Ayyagari Emi Terasawa Andreas Kuznik Zhen Chen Gaëlle Bégo-Le Bagousse Yufang Lu Elena Rizova Neil M.H. Graham Gianluca Pirozzi Marjolein De Bruin-Weller Laurent Eckert |
| author_facet | Lieneke F.M. Ariëns Abhijit Gadkari Harmieke van Os-Medendorp Rajeev Ayyagari Emi Terasawa Andreas Kuznik Zhen Chen Gaëlle Bégo-Le Bagousse Yufang Lu Elena Rizova Neil M.H. Graham Gianluca Pirozzi Marjolein De Bruin-Weller Laurent Eckert |
| author_sort | Lieneke F.M. Ariëns |
| collection | DOAJ |
| description | Dupilumab is approved for uncontrolled moderate-to-severe atopic dermatitis (AD); cyclosporine is approved for severe AD for <1 year. The efficacy/effectiveness of these treatments was compared indirectly. Regression models used pooled patient-level data to estimate response (Eczema Area and Severity Index (EASI) EASI-50/EASI-75 at weeks 12–16 and 24–30) to dupilumab 300 mg every 2 weeks (CHRONOS [NCT02260986]) or cyclosporine (University Medical Center). Models were adjusted for sex, baseline EASI, and thymus and activation-regulated chemokine level. A total of 106 patients received dupilumab (+ topical corticosteroids; + TCS), and 57 received cyclosporine (+ TCS). Among University Medical Center patients, estimated EASI-50 responders were, dupilumab vs. cyclosporine, 91% vs. 77% (p = 0.038; weeks 12–16), and 96% vs. 67% (p <0.0001; weeks 24–30); EASI-75 responders were 78% vs. 56% (p = 0.016; weeks 12–16) and 80% vs. 47% (p <0.001; weeks 24–30). Among CHRONOS patients, estimated EASI-50 responders were 90% vs. 74% (p <0.038; weeks 12–16) and 92% vs. 53% (p < 0.0001; weeks 24–30); EASI-75 responders were 75% vs. 52% (p = 0.016; weeks 12–16) and 74% vs. 40% (p <0.001; weeks 24–30), respectively. These results suggest a higher relative efficacy of dupilumab vs. cyclosporine. |
| first_indexed | 2024-04-11T20:00:44Z |
| format | Article |
| id | doaj.art-cb9d787cf6bd4596bf1c42e03864f80f |
| institution | Directory Open Access Journal |
| issn | 0001-5555 1651-2057 |
| language | English |
| last_indexed | 2024-04-11T20:00:44Z |
| publishDate | 2019-06-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Dermato-Venereologica |
| spelling | doaj.art-cb9d787cf6bd4596bf1c42e03864f80f2022-12-22T04:05:39ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572019-06-01991085185710.2340/00015555-32195486Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity IndexLieneke F.M. Ariëns0Abhijit GadkariHarmieke van Os-MedendorpRajeev AyyagariEmi TerasawaAndreas KuznikZhen ChenGaëlle Bégo-Le BagousseYufang LuElena RizovaNeil M.H. GrahamGianluca PirozziMarjolein De Bruin-WellerLaurent Eckert Department of Dermatology and Allergology, UMC Utrecht, 3508 GA Utrecht, The Netherlands. Dupilumab is approved for uncontrolled moderate-to-severe atopic dermatitis (AD); cyclosporine is approved for severe AD for <1 year. The efficacy/effectiveness of these treatments was compared indirectly. Regression models used pooled patient-level data to estimate response (Eczema Area and Severity Index (EASI) EASI-50/EASI-75 at weeks 12–16 and 24–30) to dupilumab 300 mg every 2 weeks (CHRONOS [NCT02260986]) or cyclosporine (University Medical Center). Models were adjusted for sex, baseline EASI, and thymus and activation-regulated chemokine level. A total of 106 patients received dupilumab (+ topical corticosteroids; + TCS), and 57 received cyclosporine (+ TCS). Among University Medical Center patients, estimated EASI-50 responders were, dupilumab vs. cyclosporine, 91% vs. 77% (p = 0.038; weeks 12–16), and 96% vs. 67% (p <0.0001; weeks 24–30); EASI-75 responders were 78% vs. 56% (p = 0.016; weeks 12–16) and 80% vs. 47% (p <0.001; weeks 24–30). Among CHRONOS patients, estimated EASI-50 responders were 90% vs. 74% (p <0.038; weeks 12–16) and 92% vs. 53% (p < 0.0001; weeks 24–30); EASI-75 responders were 75% vs. 52% (p = 0.016; weeks 12–16) and 74% vs. 40% (p <0.001; weeks 24–30), respectively. These results suggest a higher relative efficacy of dupilumab vs. cyclosporine. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3219 adult atopic dermatitis cyclosporine dupilumab Eczema Area and Severity Index eczema |
| spellingShingle | Lieneke F.M. Ariëns Abhijit Gadkari Harmieke van Os-Medendorp Rajeev Ayyagari Emi Terasawa Andreas Kuznik Zhen Chen Gaëlle Bégo-Le Bagousse Yufang Lu Elena Rizova Neil M.H. Graham Gianluca Pirozzi Marjolein De Bruin-Weller Laurent Eckert Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index Acta Dermato-Venereologica adult atopic dermatitis cyclosporine dupilumab Eczema Area and Severity Index eczema |
| title | Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index |
| title_full | Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index |
| title_fullStr | Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index |
| title_full_unstemmed | Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index |
| title_short | Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index |
| title_sort | dupilumab versus cyclosporine for the treatment of moderate to severe atopic dermatitis in adults indirect comparison using the eczema area and severity index |
| topic | adult atopic dermatitis cyclosporine dupilumab Eczema Area and Severity Index eczema |
| url |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3219
|
| work_keys_str_mv | AT lienekefmariens dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT abhijitgadkari dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT harmiekevanosmedendorp dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT rajeevayyagari dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT emiterasawa dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT andreaskuznik dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT zhenchen dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT gaellebegolebagousse dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT yufanglu dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT elenarizova dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT neilmhgraham dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT gianlucapirozzi dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT marjoleindebruinweller dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex AT laurenteckert dupilumabversuscyclosporineforthetreatmentofmoderatetosevereatopicdermatitisinadultsindirectcomparisonusingtheeczemaareaandseverityindex |